| Objective:Gliomas are the most common intracranial tumors. According to statistics, gliomas account for35.26%-60.69%of intracranial tumors (average44.69%) in our country. Glioma cells were invasive and expansive growth with the characteristics of a high relapse rate and high degree of malignancy. Once suffering from the disease, often with poor prognosis and survival rate. It is a serious threat to human life and health, also our normal life and work. It is still being the worst prognosis central nervous system tumor among all the malignant tumor.Therefore, new strategies to treat malignant gliomas are urgently needed.CD90is the smallest member of the immunoglobulin superfamily of cell adhesion molecules. It is a heavily glycosylated glycoprotein.The function of human CD90is not clear yet..Currently speculate CD90play important roles in cell-cell and cell-matrix recognition it is also related to neurite outgrowth,nerve regeneration,cell apoptosis and metastasis, inflammation and fibrosis. The surface protein CD90is considered a major marker for human stem cell pluripotency. It has been confirmed expressed in many stem cells and cancer stem cells(hematopoietic stem cells, bone marrow-derived mesenchymal stem cells, hepatic stem cells, as well as liver CSCs).Cancer stem cells is one of the few cell groups with characteristics of stem cells in the tumor tissue.These cells have the ability to self-renewal and multi-directional differentiation potential.A small amount of tumor stem cells exist in the tumor tissue,which can induce tumor occurrence and development.It’s the source of tumor resistance, recurrence and metastasis.Compared to normal stem cells, cancer stem cells has the following unique features:unlimited self-renewal ability, high tumorigenicity, heterogeneity, drug resistance and metastatic. In recent years, studies have shown that there are a small number of cancer stem cells in brain gliomas which have the characteristics of neural stem cell. They have the potential of self-renewal, multi-differentiation and in vivo tumorigenic. They are the root of tumor occurrence and development.This experiment using Immunohistochemical staining method and real-time PCR method to detect the CD90gene and protein expression in the normal brain tissue and different grade glioma tissue. To understand whether CD90to become judge of human glioma malignancy and prognosis. And providing a new method in the treatment of gliomas.Methods:we select56cases of cancer tissue, who received surgery to remove cancerous tissue from the second hospital of hebei medical university from Feb2013to Oct2013,and10cases of normal brain tissue which taken from Cerebral hemorrhage or Intracranial decompression. Using immunohistochemistry(IHC,SP method) and real-time luorescence quantitative PCR (RT-PCR) to detect the CD90expression. Using statistical software SPSS13.0statistical analysis of experimental data. Using Kruskal-Wallis H test to compare CD90expression between different types of clinical pathology. The inspection level α<0.05.Results:1Immunohistochemical results:The expression of CD90showed an increasing trend In the normal brain tissue, low-grade gliomas and high-grade gliomas. The CD90expression level in normal brain tissue was undetectable. And the expression level in most low-grade astrocytomas was undetectable. A small number of cases with lower level expression of CD90. In contrast, high-grade gliomas demonstrated a dramatically higher expression level of CD90. Statistical analysis showed differential expression of CD90in normal brain tissue, low grade and high grade gliomas were statistically significant. With the increase in malignant tumors, the expression of CD90was increasing. There is not statistically significant difference of CD90expression in normal brain tissue and low-grade gliomas by inter-group analysis. There are statistically significant differences between normal brain tissue and high-grade gliomas, and between low-grade gliomas and high-grade gliomas. 2RT-PCR results:Statistical analysis showed differential expression of CD90in normal brain tissue, low grade and high grade gliomas were statistically significant. With the increase in malignant tumors, the expression of CD90was increasing. There are statistically significant differences between normal brain tissue and low-grade gliomas, between normal brain tissue and high-grade gliomas, and between low-grade gliomas and high-grade gliomas by inter-group analysis.Conclusions:1The CD90levels in high-grade gliomas (WHO grade III and IV) were significantly higher than in low-grade gliomas (WHO grade I and II) and normal brains.2CD90showed high sensitivity and specificity as a marker, with high or medium expression levels in all the tested high-grade glioma tissues but barely detectable in low-grade gliomas and normal brains.3In immunohistochemical we observed the formation of vascular-like structures by CD90+cells in high-grade gliomas.4Contrast to the highly differentiated low-grade gliomas, high-grade gliomas are undifferentiated and therefore are more likely to contain undifferentiated cancer stem cells. Because the expression level of CD90is dramatically increased in high-grade gliomas compared with low-grade gliomas, CD90can be a new marker of these cancer stem cells within high-grade gliomas. |
PDF Full Text Request